Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Ocular Therapeutix will present updates on its lead asset OTX-TKI (AXPAXLI) at Clinical Trials at the Summit 2026 in Las Vegas on June 12-13. Presentations will cover the science, efficacy outcomes in neovascular AMD, safety profile, and the HELIOS program update in nonproliferative diabetic retinopathy. CEO Pravin Dugel will also participate in a fireside chat and a panel on bringing novel treatments to market.
Key figures
- Drug Name
- OTX-TKI (AXPAXLI)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.